Literature DB >> 33583167

COVID-19 and stroke: from the cases to the causes.

Giovanni Frisullo1, Irene Scala1,2, Simone Bellavia1,2, Aldobrando Broccolini1,2, Valerio Brunetti1, Roberta Morosetti1, Giacomo Della Marca1,2, Paolo Calabresi1,2.   

Abstract

During COVID-19 pandemic, a wide variety of stroke typologies have been described in patients affected by SARS-CoV-2. Investigating the case reports of acute stroke in COVID-19 patients, published since the beginning of the pandemic, we tried to trace the pathogenic mechanisms of stroke during SARS-CoV-2 infection. We conducted a systematic review analyzing demographic data, cerebrovascular risk factors, NIHSS score, vascular territory involvement and laboratory findings of 168 patients described in 89 studies, from a pool of 1243 records. Based on our results, we have identified different stroke profiles: (1) cerebral large vessel disease (CLVD) profile with a low disability, simultaneous onset of COVID-19 and stroke symptoms, good outcome and low serum levels of D-dimer and CRP; (2) intracranial bleeding (IB) profile with high disability, poor outcome and low levels of serum markers of inflammation and coagulopathy; (3) CLVD profile with a short time-lapse between COVID-19 symptoms and stroke onset, high neurological disability and very high systemic inflammatory markers; (4) multiple thrombo-embolic disease (MTED) profile with older patients, many comorbidities, disabling stroke, poor outcome, evident alteration of coagulation tests and high serum levels of both D-dimer and CRP. We therefore summarized these different profiles in a spectrum similar to that of visible light, where the violet-blue band included IB and CSVD with low inflammation and prothrombotic activity, the green-yellow band included CLVD with high inflammation and moderate prothrombotic activity and the orange-red band for MTED with moderate-high levels of inflammation and very high prothrombotic activity.
© 2021 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  COVID-19; D-dimer; SARS-COV-2; intracranial bleeding; small vessel; stroke

Mesh:

Substances:

Year:  2021        PMID: 33583167     DOI: 10.1515/revneuro-2020-0136

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  5 in total

1.  Autonomic dysfunction in non-critically ill COVID-19 patients during the acute phase of disease: an observational, cross-sectional study.

Authors:  Irene Scala; Simone Bellavia; Marco Luigetti; Valerio Brunetti; Aldobrando Broccolini; Maurizio Gabrielli; Lorenzo Zileri Dal Verme; Paolo Calabresi; Giacomo Della Marca; Giovanni Frisullo
Journal:  Neurol Sci       Date:  2022-05-24       Impact factor: 3.830

Review 2.  Autonomic Dysfunction during Acute SARS-CoV-2 Infection: A Systematic Review.

Authors:  Irene Scala; Pier Andrea Rizzo; Simone Bellavia; Valerio Brunetti; Francesca Colò; Aldobrando Broccolini; Giacomo Della Marca; Paolo Calabresi; Marco Luigetti; Giovanni Frisullo
Journal:  J Clin Med       Date:  2022-07-04       Impact factor: 4.964

3.  Neurovascular and infectious disease phenotype of acute stroke patients with and without COVID-19.

Authors:  Simone Beretta; Francesca Iannuzzi; Susanna Diamanti; Elisa Bianchi; Luca D'Urbano; Colella Elisa; Alban Rugova; Carlo Morotti Colleoni; Ettore Beghi; Paolo Bonfanti; Carlo Ferrarese
Journal:  Neurol Sci       Date:  2022-05-23       Impact factor: 3.830

4.  A Case of Bilateral Thalamic Infarcts Involving the Artery of Percheron in the Setting of COVID-19.

Authors:  Branden Wilson; Aswin Srinivasan; Tusharkumar Pansuriya; Salman Alim; Uzma Ali
Journal:  Cureus       Date:  2021-06-11

5.  Instrumental Evaluation of COVID-19 Related Dysautonomia in Non-Critically-Ill Patients: An Observational, Cross-Sectional Study.

Authors:  Simone Bellavia; Irene Scala; Marco Luigetti; Valerio Brunetti; Maurizio Gabrielli; Lorenzo Zileri Dal Verme; Serenella Servidei; Paolo Calabresi; Giovanni Frisullo; Giacomo Della Marca
Journal:  J Clin Med       Date:  2021-12-14       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.